Therefore, PSMA is an excellent target for specific imaging and targeted therapy for prostate cancer; with 18F-PSMA-1007 PET/CT, disease recurrence could be identified at a low level of serum PSA (9). This evidence concerns the gene FOLH1 and prostate cancer.